vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and SYNAPTICS Inc (SYNA). Click either name above to swap in a different company.

SYNAPTICS Inc is the larger business by last-quarter revenue ($302.5M vs $267.3M, roughly 1.1× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 13.2%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 12.9%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Synaptics, Inc. is an American neural network technologies and computer-to-human interface devices development company based in San Jose, California. It develops touchpads and fingerprint biometrics technology for computer laptops; touch, display driver, and fingerprint biometrics technology for smartphones; and touch, video and far-field voice, low-power AI processors, and wireless technology for smart home devices, wearables, and automobiles. Synaptics sells its products to original equipme...

ASND vs SYNA — Head-to-Head

Bigger by revenue
SYNA
SYNA
1.1× larger
SYNA
$302.5M
$267.3M
ASND
Growing faster (revenue YoY)
ASND
ASND
+29.1% gap
ASND
42.3%
13.2%
SYNA
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
12.9%
SYNA

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ASND
ASND
SYNA
SYNA
Revenue
$267.3M
$302.5M
Net Profit
$-14.8M
Gross Margin
90.5%
43.5%
Operating Margin
-5.0%
Net Margin
-4.9%
Revenue YoY
42.3%
13.2%
Net Profit YoY
-922.2%
EPS (diluted)
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
SYNA
SYNA
Q4 25
$267.3M
$302.5M
Q3 25
$230.7M
$292.5M
Q2 25
$170.7M
$282.8M
Q1 25
$109.0M
$266.6M
Q4 24
$187.8M
$267.2M
Q3 24
$62.5M
$257.7M
Q2 24
$38.9M
$247.4M
Q1 24
$103.6M
$237.3M
Net Profit
ASND
ASND
SYNA
SYNA
Q4 25
$-14.8M
Q3 25
$-65.9M
$-20.6M
Q2 25
$-42.0M
$-4.7M
Q1 25
$-102.2M
$-21.8M
Q4 24
$1.8M
Q3 24
$-107.1M
$-23.1M
Q2 24
$-118.1M
$208.3M
Q1 24
$-141.5M
$-18.1M
Gross Margin
ASND
ASND
SYNA
SYNA
Q4 25
90.5%
43.5%
Q3 25
89.5%
42.6%
Q2 25
80.1%
43.0%
Q1 25
82.6%
43.4%
Q4 24
91.9%
45.7%
Q3 24
80.6%
46.9%
Q2 24
68.2%
45.8%
Q1 24
92.1%
46.5%
Operating Margin
ASND
ASND
SYNA
SYNA
Q4 25
-5.0%
Q3 25
5.1%
-7.9%
Q2 25
-33.5%
-8.6%
Q1 25
-103.2%
-9.9%
Q4 24
-5.7%
Q3 24
-167.3%
-11.0%
Q2 24
-370.2%
-12.6%
Q1 24
-51.2%
-7.3%
Net Margin
ASND
ASND
SYNA
SYNA
Q4 25
-4.9%
Q3 25
-28.5%
-7.0%
Q2 25
-24.6%
-1.7%
Q1 25
-93.7%
-8.2%
Q4 24
0.7%
Q3 24
-171.5%
-9.0%
Q2 24
-303.9%
84.2%
Q1 24
-136.6%
-7.6%
EPS (diluted)
ASND
ASND
SYNA
SYNA
Q4 25
$-0.38
Q3 25
$-0.53
Q2 25
$-0.13
Q1 25
$-0.56
Q4 24
$0.05
Q3 24
$-0.58
Q2 24
$5.28
Q1 24
$-0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
SYNA
SYNA
Cash + ST InvestmentsLiquidity on hand
$665.3M
$437.4M
Total DebtLower is stronger
$836.0M
Stockholders' EquityBook value
$-175.8M
$1.4B
Total Assets
$1.4B
$2.6B
Debt / EquityLower = less leverage
0.60×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
SYNA
SYNA
Q4 25
$665.3M
$437.4M
Q3 25
$582.2M
$459.9M
Q2 25
$533.6M
$452.5M
Q1 25
$559.4M
$421.4M
Q4 24
$604.3M
$596.1M
Q3 24
$675.6M
$853.6M
Q2 24
$279.4M
$876.9M
Q1 24
$345.9M
$828.6M
Total Debt
ASND
ASND
SYNA
SYNA
Q4 25
$836.0M
Q3 25
$835.4M
Q2 25
$834.8M
Q1 25
$834.2M
Q4 24
$832.5M
Q3 24
Q2 24
$983.5M
Q1 24
Stockholders' Equity
ASND
ASND
SYNA
SYNA
Q4 25
$-175.8M
$1.4B
Q3 25
$-188.0M
$1.4B
Q2 25
$-202.6M
$1.4B
Q1 25
$-205.0M
$1.4B
Q4 24
$-114.2M
$1.4B
Q3 24
$-105.1M
$1.5B
Q2 24
$-346.8M
$1.5B
Q1 24
$-257.2M
$1.2B
Total Assets
ASND
ASND
SYNA
SYNA
Q4 25
$1.4B
$2.6B
Q3 25
$1.2B
$2.6B
Q2 25
$1.2B
$2.6B
Q1 25
$1.1B
$2.6B
Q4 24
$1.3B
$2.5B
Q3 24
$1.2B
$2.8B
Q2 24
$819.0M
$2.8B
Q1 24
$866.7M
$2.5B
Debt / Equity
ASND
ASND
SYNA
SYNA
Q4 25
0.60×
Q3 25
0.60×
Q2 25
0.60×
Q1 25
0.60×
Q4 24
0.60×
Q3 24
Q2 24
0.67×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
SYNA
SYNA
Operating Cash FlowLast quarter
$58.2M
$29.8M
Free Cash FlowOCF − Capex
$18.2M
FCF MarginFCF / Revenue
6.0%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$154.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
SYNA
SYNA
Q4 25
$58.2M
$29.8M
Q3 25
$30.2M
Q2 25
$57.2M
Q1 25
$-15.5M
$73.4M
Q4 24
$-330.7M
$22.8M
Q3 24
$-11.4M
Q2 24
$65.0M
Q1 24
$-109.7M
$-13.7M
Free Cash Flow
ASND
ASND
SYNA
SYNA
Q4 25
$18.2M
Q3 25
$18.0M
Q2 25
$50.6M
Q1 25
$68.0M
Q4 24
$18.1M
Q3 24
$-20.5M
Q2 24
$57.3M
Q1 24
$-22.7M
FCF Margin
ASND
ASND
SYNA
SYNA
Q4 25
6.0%
Q3 25
6.2%
Q2 25
17.9%
Q1 25
25.5%
Q4 24
6.8%
Q3 24
-8.0%
Q2 24
23.2%
Q1 24
-9.6%
Capex Intensity
ASND
ASND
SYNA
SYNA
Q4 25
3.8%
Q3 25
4.2%
Q2 25
2.3%
Q1 25
2.0%
Q4 24
1.8%
Q3 24
3.5%
Q2 24
3.1%
Q1 24
3.8%
Cash Conversion
ASND
ASND
SYNA
SYNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
12.67×
Q3 24
Q2 24
0.31×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASND
ASND

Segment breakdown not available.

SYNA
SYNA

Enterprise And Automotive Product Applications$161.1M53%
Internet Of Things Product Applications$93.2M31%
Mobile Product Applications$48.2M16%

Related Comparisons